 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 June 1993 | Volume 118 Issue 11 | Pages 865-866
The effects of liver transplantation and the obligate use of cyclosporine on the subsequent clinical course of nine patients with sarcoidosis were examined. Two comparison groups, each consisting of 18 patients without sarcoidosis, were also studied. The liver allograft recipients received either cyclosporine or FK 506 as their primary immunosuppressive agent. Patient and graft survival were assessed for all three groups. In patients with sarcoidosis before transplantation, evidence for continued disease activity after transplantation was also assessed. Patient and allograft survival were excellent. No clinical evidence of continued disease activity was noted. Thus, the presence of sarcoidosis is not a contraindication for liver transplantation in otherwise appropriate candidates for the procedure.
Author and Article Information
From the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
BRIEF REPORT
Clinical Course after Liver Transplantation in Patients with Sarcoidosis
Requests for Reprints: F. Adrian Casavilla, MD, Transplantation Institute, Falk 5C, Pittsburgh, PA 15213.
This article has been cited by other articles:
|
|
 |
|
  G. Hunninghake Statement on Sarcoidosis Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 736 - 755. [Full Text]
|
|
|
|
 |
|
 L. S. Newman, C. S. Rose, and L. A. Maier Sarcoidosis N. Engl. J. Med., April 24, 1997; 336(17): 1224 - 1234. [Full Text] [PDF]
|
|
Article
